Rallybio Corp (RLYB) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Rallybio is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases, primarily in complement dysregulation, hematology, and metabolic disorders. The company's lead program is RLYB116, a complement component 5 inhibitor. In April 2025, the company announced the discontinuation of its RLYB212 program for fetal and neonatal alloimmune thrombocytopenia (FNAIT) due to pharmacokinetic data failing to achieve target concentrations.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $212 | $0 |
| Net Loss | $(9,439) | $(19,029) |
| Net Loss Per Share (Basic & Diluted) | $(0.21) | $(0.47) |
| Research & Development Expenses | $5,725 | $12,936 |
| General & Administrative Expenses | $4,157 | $6,851 |
| Cash, Cash Equivalents & Marketable Securities | $54,495 | $60,313 |
| Accumulated Deficit | $(302,459) | $(254,274) |
Note: Revenue consists of collaboration and license revenue recognized from a Johnson & Johnson agreement. The company has no commercial product sales.
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately $9.6 million (50%) compared to Q1 2024, driven primarily by significant cost reductions.
- Expense Reductions:
- R&D Expenses: Decreased by $7.2 million. This was largely due to a $3.2 million reduction in costs for the discontinued RLYB212 program and a $2.6 million decrease in personnel expenses following a workforce reduction in March 2024.
- G&A Expenses: Decreased by $2.7 million, primarily due to lower payroll and personnel costs.
- Revenue Recognition: The company recognized $0.2 million in revenue in Q1 2025, compared to zero in Q1 2024, related to performance obligations under the J&J collaboration agreement.
- Investment in Joint Venture: The company recorded a loss of $0.6 million on its investment in RE Ventures I, LLC, compared to $0.7 million in the prior year.
Guidance, Outlook, and Risks
- Liquidity: As of March 31, 2025, the company held $54.5 million in cash and marketable securities. Management expects these funds to be sufficient to operate into the first half of 2027. However, the company will require substantial additional capital to complete development and commercialization of its product candidates.
- Program Updates:
- RLYB116: A confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study in healthy volunteers is planned for initiation in Q2 2025, with data expected in Q3/Q4 2025.
- RLYB212: Discontinued in April 2025 after Phase 2 PK results failed to meet efficacy targets.
- Preclinical: Continued development of REV102 (hypophosphatasia) and RLYB332 (iron overload).
- Subsequent Workforce Reduction: On May 2, 2025, the company approved a new workforce reduction eliminating approximately 40% of positions to focus resources on RLYB116 and preclinical programs. The company expects to incur approximately $1.7 million in charges related to this action in Q2 2025.
- Listing Status Risk: The company received notice from Nasdaq on February 24, 2025, that its stock price had been below the $1.00 minimum bid price requirement for 30 consecutive days. The company has until August 25, 2025, to regain compliance or risk delisting.
Investor Verification Checklist
- Verify the timeline and budget for the upcoming RLYB116 confirmatory PK/PD study scheduled for Q2 2025.
- Monitor the company's progress in regaining compliance with Nasdaq's $1.00 minimum bid price requirement by the August 25, 2025 deadline.
- Assess the impact of the May 2025 workforce reduction (40% of positions) on the company's ability to execute its development plan.
- Review the company's cash burn rate and confirm the runway estimate extending into the first half of 2027.
- Understand the revenue recognition mechanics of the J&J collaboration agreement and the likelihood of future milestone payments given the discontinuation of the RLYB212 program.